tetano
Editor, Senior Moderator
Mol Ther
. 2024 Feb 9:S1525-0016(24)00080-7.
doi: 10.1016/j.ymthe.2024.02.011. Online ahead of print. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
Namei Wu[SUP] 1 [/SUP], Jiachen Zhang[SUP] 2 [/SUP], Yanqiong Shen[SUP] 2 [/SUP], Xinghai Zhang[SUP] 3 [/SUP], Jinge Zhou[SUP] 3 [/SUP], Yan Wu[SUP] 3 [/SUP], Entao Li[SUP] 2 [/SUP], Xiaoming Meng[SUP] 4 [/SUP], Xia Chuai[SUP] 3 [/SUP], Sandra Chiu[SUP] 2 [/SUP], Yucai Wang[SUP] 5 [/SUP]
Affiliations
As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions of infants, elderly individuals, and immunocompromised people globally. Exacerbating the situation is the fact that co-infection with multiple viruses is occurring, something which has greatly increased the clinical severity of the infections. Thus, our team developed a bivalent vaccine that delivered messenger RNAs (mRNAs) encoding SARS-CoV-2 Omicron spike (S) and RSV fusion (F) proteins simultaneously, SF-LNP, which induced S and F protein-specific binding antibodies and cellular immune responses in BALB/c mice. Moreover, SF-LNP immunization effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection. Notably, our study pointed out the antigenic competition problem of bivalent vaccines and provided a solution. Overall, our results demonstrated the potential of preventing two infectious diseases with a single vaccine and provided a paradigm for the subsequent design of multivalent vaccines.
Keywords: antigen competition; bivalent vaccine; lipid nanoparticle; mRNA; respiratory infectious disease; respiratory syncytial virus; severe acute respiratory syndrome coronavirus 2.
. 2024 Feb 9:S1525-0016(24)00080-7.
doi: 10.1016/j.ymthe.2024.02.011. Online ahead of print. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
Namei Wu[SUP] 1 [/SUP], Jiachen Zhang[SUP] 2 [/SUP], Yanqiong Shen[SUP] 2 [/SUP], Xinghai Zhang[SUP] 3 [/SUP], Jinge Zhou[SUP] 3 [/SUP], Yan Wu[SUP] 3 [/SUP], Entao Li[SUP] 2 [/SUP], Xiaoming Meng[SUP] 4 [/SUP], Xia Chuai[SUP] 3 [/SUP], Sandra Chiu[SUP] 2 [/SUP], Yucai Wang[SUP] 5 [/SUP]
Affiliations
- PMID: 38341613
- DOI: 10.1016/j.ymthe.2024.02.011
As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions of infants, elderly individuals, and immunocompromised people globally. Exacerbating the situation is the fact that co-infection with multiple viruses is occurring, something which has greatly increased the clinical severity of the infections. Thus, our team developed a bivalent vaccine that delivered messenger RNAs (mRNAs) encoding SARS-CoV-2 Omicron spike (S) and RSV fusion (F) proteins simultaneously, SF-LNP, which induced S and F protein-specific binding antibodies and cellular immune responses in BALB/c mice. Moreover, SF-LNP immunization effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection. Notably, our study pointed out the antigenic competition problem of bivalent vaccines and provided a solution. Overall, our results demonstrated the potential of preventing two infectious diseases with a single vaccine and provided a paradigm for the subsequent design of multivalent vaccines.
Keywords: antigen competition; bivalent vaccine; lipid nanoparticle; mRNA; respiratory infectious disease; respiratory syncytial virus; severe acute respiratory syndrome coronavirus 2.